Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours

European Radiology

Volumn 21, Issue 11, 2011, Pages 2408-2416

  Kumar, Rakesh ^a   Sharma, Punit ^a   Garg, Pramod ^a   Karunanithi, Sellam ^a   Naswa, Niraj ^a   Sharma, Raju ^a   Thulkar, Sanjay ^a   Lata, Sneh ^a   Malhotra, Arun ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

68Ga DOTATOC; CECT; NET; Pancreas; PET CT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; OCTREOTIDE;

ADULT; ARTICLE; BIOPSY; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EVALUATION AND FOLLOW UP; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADULT; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053927063     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2199-y     Document Type: Article

References (34)

1. IM Modlin KD Lye M Kidd 2003 A 5-decade analysis of 13,715 carcinoid tumors Cancer 97 934 959 12569593 10.1002/cncr.11105
2. GA Kaltsas GM Besser AB Grossman 2004 The diagnosis and medical management of advanced neuroendocrine tumors Endocr Rev 25 458 511 15180952 10.1210/er.2003-0014 1:CAS:528:DC%2BD2cXlvVeltLs%3D
3. B Eriksson K Oberg M Stridsberg 2000 Tumor markers in neuroendocrine tumors Digestion 62 33 38 10940685 10.1159/000051853 1:CAS:528: DC%2BD3cXmtVaku7w%3D
4. K Oberg B Eriksson 2005 Endocrine tumours of the pancreas Best Pract Res Clin Gastroenterol 19 753 781 16253899 10.1016/j.bpg.2005.06.002
5. B Ueberberg H Tourne A Redman MK Walz KW Schmid K Mann, et al. 2005 Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland Horm Metab Res 37 12 722 728 16372224 10.1055/s-2005-921092 1:CAS:528:DC%2BD28XisVSjtw%3D%3D
6. M Papotti U Kuma M Volante C Pecchiono YC Patel 2001 Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid Clin Endocrinol 54 641 649 10.1046/j.1365-2265.2001.01175.x 1:CAS:528:DC%2BD3MXks1Kgsb4%3D
7. TanakaY OdaY T Naruse R Sasanabe FH TsubamotoM 2002 Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors Surg Today 32 8 690 694 10.1007/s005950200128
8. M Papotti M Bongiovanni M Volante E Allia S Landolfi L Helboe, et al. 2002 Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis Virchows Arch 440 5 461 475 12021920 10.1007/s00428-002-0609-x 1:CAS:528:DC%2BD38Xjs1yhsLc%3D
9. JC Reubi 1995 Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging J Nucl Med 36 1825 1835 7562050 1:CAS:528: DyaK2MXpsFagtbY%3D
10. JC Reubi JC Schar B Waser S Wenger A Heppeler JS Schmitt HR Macke 2000 Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 273 282 10774879 10.1007/s002590050034 1:CAS:528: DC%2BD3cXhsVWns7w%3D
11. M Miederer S Seidl A Buck K Scheidhauer HJ Wester M Schwaiger A Perren 2009 Correlation of immune-histopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT Eur J Nucl Med Mol Imaging 36 48 52 18807033 10.1007/s00259-008-0944-5 1:CAS:528:DC%2BD1cXhsVGqurzJ
12. G Kaltsas JJ Mukherjee AB Grossman 2001 The value of radiolabeled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours Clin Endocrinol 55 575 587 10.1046/j.1365-2265.2001.01396.x 1:CAS:528: DC%2BD3MXptVGru78%3D
13. G Kaltsas A Rockall D Papadogias R Reznek AB Grossman 2004 Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours Eur J Endocrinol 151 15 27 15248818 10.1530/eje.0.1510015 1:CAS:528:DC%2BD2cXmsFelur0%3D
14. M Hofmann H Maecke R Börner E Weckesser P Schöffski L Oei, et al. 2001 Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data Eur J Nucl Med 28 1751 1757 11734911 10.1007/s002590100639 1:CAS:528:DC%2BD3MXosFagurs%3D
15. I Buchmann M Henze S Engelbrecht M Eisenhut A Runz M Schäfer, et al. 2007 Comparison of 68Ga-DOTATOC PET and 111 In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 34 1617 1626 17520251 10.1007/s00259-007-0450-1 1:STN:280:DC%2BD2srmtlaisQ%3D%3D
16. J Kowalski M Henze J Schuhmacher, et al. 2003 Evaluation of positron emission tomography imaging using [68Ga]-DOTA- D- Phe(1)- Tyr(3)-octreotide in comparison to [ 111 In]- DTPAOC SPECT. First results in patients with neuroendocrine tumors Mol Imaging Biol 5 42 48 14499161 10.1016/S1536-1632(03) 00038-6
17. M Gabriel C Decristoforo D Kendler G Dobrozemsky D Heute C Uprimny, et al. 2007 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatinreceptor scintigraphy and CT J Nucl Med 48 508 518 17401086 10.2967/jnumed.106.035667 1:CAS:528:DC%2BD2sXhtVert7jF
18. A Heppeler S Froidevaux HR Mäcke 1999 Radiometal-labeledmacrocyclic chelator derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptormediated internal radiotherapy Chem Eur J 5 1974 1981 10.1002/(SICI)1521-3765(19990702)5:7<1974::AID-CHEM1974>3.0. CO;2-X 1:CAS:528:DyaK1MXksVansbY%3D
19. KP Zhernosekov DV Filosofor RP Baum, et al. 2007 Processing of generator produced 68Ga for medical applications J Nucl Med 48 1741 1748 17873136 10.2967/jnumed.107.040378 1:CAS:528:DC%2BD2sXht1GlurnE
20. US National Cancer Institute. SEER Database. http://seer.cancer.gov/ (accessed Nov 15, 2007).
21. M Stridsberg K Oberg Q Li, et al. 1995 Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours J Endocrinol 144 49 59 7891024 10.1677/joe.0. 1440049 1:CAS:528:DyaK2MXjtlCktL4%3D
22. IM Modlin M Kidd I Latich, et al. 2005 Current status of gastrointestinal carcinoids Gastroenterology 128 1717 1751 15887161 10.1053/j.gastro.2005.03.038
23. MA Anderson S Carpenter NW Thompson, et al. 2000 Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas Am J Gastroenterol 95 2271 2277 11007228 10.1111/j.1572-0241. 2000.02480.x 1:STN:280:DC%2BD3cvltFGnsg%3D%3D
24. F Gibril RT Jensen 2004 Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours Dig Liver Dis 36 S106 S120 15077919 10.1016/j.dld.2003.11.024 1:CAS:528:DC%2BD2cXjsFOns7w%3D
25. Gastrointestinal carcinoid tumours (2007) In: Modlin IM, Gustafsson BI, Kidd M, eds. Advances in digestive disease. Bethesda, MD: AGA Institute Press, pp 203-218.
26. U Kumar R Sasi S Suresh A Patel M Thangaraju P Metrakos, et al. 1999 Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis Diabetes 48 1 77 85 9892225 10.2337/diabetes.48.1.77 1:CAS:528:DyaK1MXhvV2qtA%3D%3D
27. T Arita T Kuramitsu M Kawamura T Matsumoto N Matsunaga K Sugi, et al. 1995 Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes Thorax 50 1267 1269 8553299 10.1136/thx.50.12.1267 1:STN:280: DyaK287jvVCkuw%3D%3D
28. DM Einstein AA Singer WA Chilcote RK Desai 1991 Abdominal lymphadenopathy: spectrum of CT findings Radiographics 11 457 472 1852937 1:STN:280:DyaK3MzgsFKisQ%3D%3D
29. BH Gross GM Glatzer MB Orringer 1988 Bronchogenic carcinoma metastatic to normalsized nodes: frequency and significance Radiology 166 71 74 3336704 1:STN:280:DyaL1c%2FpvVWgug%3D%3D
30. JC Reubi JC Schär B Waser S Wenger A Heppeler JS Schmitt, et al. 2000 Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med Mol Imaging 27 273 282 10.1007/s002590050034 1:CAS:528: DC%2BD3cXhsVWns7w%3D
31. M Buchmann S Henze M Engelbrecht A Eisenhut M Runz T Schäfer, et al. 2007 Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 34 1617 1626 17520251 10.1007/s00259-007-0450-1 1:STN:280:DC%2BD2srmtlaisQ%3D%3D
32. J Ruf F Heuck J Schiefer T Denecke F Elgeti A Pascher, et al. 2010 Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors Neuroendocrinology 91 101 109 19996582 10.1159/000265561 1:CAS:528:DC%2BC3cXotVWrtw%3D%3D
33. V Prasad V Ambrosini M Hommann D Hoersch S Fanti RP Baum 2010 Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT Eur J Nucl Med Mol Imaging 37 67 77 19618183 10.1007/s00259-009-1205-y 1:CAS:528:DC%2BD1MXhsFCktLrF
34. I Kayani JB Bomanji A Groves G Conway S Gacinovic T Win, et al. 2008 Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG Cancer 112 2447 2455 18383518 10.1002/cncr.23469